


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.



¹ If no confirmed epithelial cancer diagnosis, see [Appendix A](#) for evaluation of undiagnosed cancer

² For tertiary centers, mammogram of ipsilateral breast is not needed if outside mammogram of diagnostic quality was within 2 months and is available for review. IBC is painful and mammogram may not be tolerable for some patients.

³ If suspicious MRI finding in the contralateral breast, then MRI-directed or second look ultrasound can be performed

⁴ If MRI is performed, bilateral ultrasound of breast is not needed

⁵ If PET/CT has been performed before ultrasound, then bilateral ultrasound of the nodal basins may not be necessary

⁶ Refer to <https://www.komen.org/ibc-calculator-intro/>

⁷ Perform nodal biopsy on the node which would have maximum impact on nodal staging and treatment. If both axillary and supraclavicular nodes appear suspicious, perform biopsy on supraclavicular node only.

⁸ Skin punch not required

⁹ Consult plastic surgery for evaluation to perform chest wall closure and immediate lymphatic reconstruction (pLVB)


¹⁰ Consult Plastic Surgery for patients who are interested in having reconstructive surgery later and want to discuss plastic surgery prior to modified radical mastectomy

¹¹ See [Physical Activity](#), [Nutrition](#), [Obesity Screening and Management](#), and [Tobacco Cessation Treatment](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

¹² Contact the clinical trial coordinator of the IBC registry at MD Anderson

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.



¹ Borderline resectable cases should be monitored closely and proceed to surgery if the tumor is progressing or the window for surgery and radiation therapy will be lost

² For extensive skin involvement, ensure that all grossly abnormal skin is resected. Plastic surgery assistance may be required with chest wall closure or immediate lymphatic reconstruction.

³ Breast surgery is performed 4-6 weeks after neoadjuvant therapy

⁴ See [Appendix C: Principles of Radiation Therapy](#)

⁵ See [Appendix E: Refractory, Recurrent or Metastatic Breast Cancer Systemic Therapy Treatment Options](#)

⁶ GCC should be initiated by the Primary Oncologist. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The Advance Care Planning (ACP) note should be used to document GCC discussion. Refer to [GCC home page](#) (for internal use only).

⁷ Next-generation sequencing (NGS) should be done for patients who eligible for systemic therapy

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.

SURVEILLANCE

- Physical exam at least every 3-6 months for 2 years from date of diagnosis, every 6 months for 3 years, then annually thereafter
- If 5 years from the completion of all local¹ and adjuvant medical therapy **and** no evidence of disease, refer to [Survivorship – Invasive Breast algorithm](#)
- Postmenopausal patients receiving tamoxifen should have close monitoring for symptoms of uterine cancer or endometrial hyperplasia
- Imaging is guided based on patient complaints and physical examination findings
- Assess bone health² (see [Survivorship – Breast Cancer: Bone Health algorithm](#))
- Cardiac screening (see [Survivorship – Adult Cardiovascular Screening algorithm](#))
- Encourage age appropriate cancer and general health guidelines including sexual health/fertility
- Genito-urinary assessment (e.g., hot flashes, vaginal dryness/atrophy, dyspareunia, urinary incontinence)
- Neuropathy assessment
- Neuropsychiatry for cognitive dysfunction symptoms
- Monitor for endocrinopathies
- Prospective lymphedema screening program
- Referral to Physical Therapy for upper extremity range of motion and muscle strength assessment and/or evaluation and treatment of lymphedema
- Consider referral to Physical Medicine and Rehabilitation for radiation induced restricted range of motion unrelieved by physical therapy to discuss additional strategies for improved physician functioning including botulinum toxin injections
- Consider referral to Plastic Surgery for autologous fat grafting to reduce radiation related fibrosis, delayed breast reconstruction, or for lymphedema surgery

➔ See [Page 4](#) for evaluation of local recurrence

¹ Completion of all treatment with the exception of endocrine agents


² All postmenopausal women (especially those on aromatase inhibitors) and premenopausal women on ovarian suppression

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.

EVALUATION FOR LOCAL RECURRENCE

TREATMENT FOR RECURRENCE



¹ For diffuse metastasis, consider clinical trials and see [Breast Cancer – Metastatic Disease algorithm](#)

² For isolated regional nodal recurrence, multidisciplinary review after systemic therapy for optimal local regional management

³ See [Appendix B: Neoadjuvant Systemic Therapy Options](#)

⁴ See [Appendix D: Adjuvant Systemic Therapy Options](#)

⁵ Surveillance upon completion of all therapy, see [Page 3](#)

⁶ GCC should be initiated by the Primary Oncologist. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The ACP note should be used to document GCC discussion. Refer to [GCC home page](#) (for internal use only).


⁷ See [Appendix E: Refractory, Recurrent or Metastatic Breast Cancer Systemic Therapy Treatment Options](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX A: Undiagnosed Breast Cancer Evaluation

Inflammatory breast syndrome¹:

- Breast skin changes
- Swelling/engorgement of the breast
- Erythema or other skin discoloration
- Nipple abnormalities



¹ Most often benign, but important to rule out inflammatory breast cancer
² Refer to department-specific standards related to pregnancy and imaging
³ If continued symptoms or progression, consider specialty consult with Infectious Diseases and/or Dermatology, and re-image at 3 months

APPENDIX B: Neoadjuvant Systemic Therapy Options¹

Molecular Subtypes	First Line Therapy	Considerations
TNBC	Pembrolizumab 200 mg IV every 3 weeks plus weekly paclitaxel 80 mg/m ² IV for 12 doses with carboplatin AUC 1.5 IV weekly for 12 weeks or AUC 5 IV every 3 weeks for 4 cycles followed by AC with pembrolizumab 200 mg every 3 weeks for 4 cycles, then continue pembrolizumab 200 mg every 3 weeks to complete one year of treatment or If contraindication to pembrolizumab, weekly paclitaxel for 12 doses or dose dense paclitaxel every 2 weeks for 4 cycles followed by or preceded by dose dense AC every 2 weeks or AC every 3 weeks	Consider adding carboplatin to paclitaxel (only for second option)
ER+	Weekly paclitaxel 80 mg/m ² IV for 12 doses or dose dense paclitaxel 175 mg/m ² IV every 2 weeks for 4 cycles, followed by or preceded by dose dense AC every 2 weeks or AC every 3 weeks	
HER2+	AC (dose dense every 2 weeks or every 3 weeks for 4 cycles) for 4 cycles followed by THP every 3 weeks for 4 cycles or THP every 3 weeks for 4 cycles followed by AC (dose dense for every 2 weeks or every 3 weeks for 4 cycles)	TCHP every 3 weeks for 6 cycles as a second choice

Chemotherapy Regimen	Dose
AC	Doxorubicin 60 mg/m ² IV Cyclophosphamide 600 mg/m ² IV
THP	Docetaxel 75 mg/m ² IV PLUS IV or subcutaneous options: Trastuzumab 8 mg/kg IV loading dose, followed by 6 mg/kg IV Pertuzumab 840 mg IV loading dose, followed by 420 mg IV maintenance dose or Pertuzumab 1,200 mg/trastuzumab 600 mg/hyaluronidase 30,000 units subcutaneously loading dose, followed by pertuzumab 600 mg/trastuzumab 600 mg/hyaluronidase 20,000 units subcutaneously maintenance dosing

Chemotherapy Regimen	Dose
TCHP	Docetaxel 75 mg/m ² IV Carboplatin AUC 6 IV PLUS IV or subcutaneous options: Trastuzumab 8 mg/kg IV loading dose, followed by 6 mg/kg IV Pertuzumab 840 mg IV loading dose, followed by 420 mg IV maintenance dose or Pertuzumab 1,200 mg/trastuzumab 600 mg/hyaluronidase 30,000 units subcutaneously loading dose, followed by pertuzumab 600 mg/trastuzumab 600 mg/hyaluronidase 20,000 units subcutaneously maintenance dosing

AC = doxorubicin and cyclophosphamide

THP = docetaxel, trastuzumab, pertuzumab

TCHP = docetaxel, carboplatin, trastuzumab, pertuzumab

TNBC = triple negative breast cancer

¹ Refer to NCCN Guidelines for specific doses and number of cycles

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX C: Principles of Radiation Therapy

General Principles

- Adjuvant radiation therapy should begin within 4 weeks after final surgical resection, when feasible
- Radiation therapy should be completed before or, as appropriate, concurrent with adjuvant systemic therapy (e.g., pembrolizumab or HER2-directed therapy). In the setting of twice daily (BID) fractionation, consider holding concurrent systemic therapy during the second half of the treatment course with the development of subjectively excess acute toxicity.

Commonly used Radiation Prescriptions

Age > 45 years and pathologic complete response (pCR)	Daily (QD) fractionation: • 50 Gy in 25 daily fractions to the chest wall and regional lymph nodes (axilla, infraclavicular fossa (ICLV), supraclavicular fossa (SCV), and internal mammary chain (IMC) • 10 Gy in 5 daily fractions sequential boost to the chest wall flaps and unresected clinically involved lymph nodes with pCR
Age ≤ 45 years or no pCR	Twice daily (BID) fractionation: • 51 Gy in 34 twice daily fractions to the chest wall and regional lymph nodes (axilla, ICLV, SCV, and IMC) • 15 Gy in 10 twice daily fractions sequential boost to the chest wall flaps and unresected clinically involved lymph nodes Daily (QD) fractionation (for patients who decline BID fractionation): • 50 Gy in 25 daily fractions to the chest wall and regional lymph nodes (axilla, ICLV, SCV, and IMC) • 16 Gy in 8 daily fractions sequential boost to the chest wall flaps and unresected clinically involved lymph nodes with pCR

Treatment Planning

- 3-dimensional (3D) CT-based simulation and treatment planning should be performed utilizing adequate immobilization for reproducibility
- Wire markers are placed along any scars, drains, and anatomical boundaries to facilitate treatment planning
- 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) may be utilized for both the primary treatment plan and/or the boosts, depending on clinical benefits. VMAT should be strongly considered for cN3 disease where sites of cN3 disease should be boosted.
- In 3D-CRT plans using tangents with electron fields for the IMC, junctions between fields may be overlapped 3 mm to ensure the skin is not underdosed. This may subsequently be reduced or omitted after treatment plan review to decrease heterogeneity.

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX C: Principles of Radiation Therapy - continued

Target Volume Delineation

- Initial cross-sectional diagnostic imaging (CT scan with IV contrast; PET scan) should be reviewed and fused to the CT simulation planning scan to assist with accurate target volume delineation of gross target volumes (GTVs) and clinical target volumes (CTVs)
- The Radiotherapy Comparative Effectiveness (RADCOMP) guidelines for target volume delineation of CTVs should be utilized for all IMRT/VMAT cases for patients with IBC
- CTVs will be subtracted from organs at risk (OARs), with attention to the thyroid and esophagus, as well as 3mm from the skin to create planning CTVs (pCTVs)
- CTVs and pCTVs should ensure volume(s) delineated for clinically involved unresected lymph nodes as visualized on cross-sectional diagnostic imaging prior to chemotherapy (pGTV_PreChemo_LN) are included, with a 1-2 cm margin expansion, edited for clinical areas at risk and constrained to the primary elective nodal pCTVs
- Planning treatment volumes (PTVs) will be expanded from delineated pCTVs for all target volumes and limited 3 mm from the skin, as directed below, when using IMRT/VMAT treatment planning
- Planning organ at risk volume (PRV) of the esophagus (PRV_Esophagus) should be created as a 3 mm expansion from the esophagus. The PTV_SCV (supraclavicular) will be subtracted from the PRV_Esophagus to facilitate esophageal constraints, ensuring coverage of the pre-chemotherapy GTVs of unresected lymph nodes (pGTV_PreChemo_LN) is not compromised.
- Boost volumes of unresected clinically involved lymph nodes (pCTV_PreChemo_LN) should include a 1-2 cm expansion, at minimum, of the pGTV_PreChemo_LN and limited to the primary pCTV nodal volume(s)

Chest wall	• The radiation fields/chest wall target volumes should include all skin determined to be clinically involved at diagnosis prior to chemotherapy plus a 3 cm margin (refer to medical photography obtained at diagnosis, if available) • The chest wall musculature should be included with or without the ribs per physician discretion • All drain sites should be included in the radiation fields/chest wall target volumes plus a 1-2 cm margin • Care must be taken to review the scar extent and ensure the medial field provides 3 cm of dosimetric cover beyond the scar, even if this involves treating the opposite breast
Grossly involved lymph nodes	Lymph nodes that were grossly involved at diagnosis as visualized on cross-sectional diagnostic imaging prior to chemotherapy should be delineated on the planning scan and edited for clinical areas at risk (pGTV_PreChemo_LN)
Uninvolved Nodal Volumes CTV_Axilla CTV_SCV CTV_IMC	• The undissected and dissected axillary basins, ICLV/axillary apex, SCLV (anterior and posterior basins), and IMC nodes within the first 3 intercostal spaces (at minimum) should be delineated as mandatory target volumes on the CT planning scan • The posterior neck nodes should be included in the SCV nodal target volume • If there is clinical involvement of internal mammary nodes at diagnosis, consider including the 4th or even 5th intercostal spaces of the IMC depending on initial node involvement and normal tissue constraints • The SCV nodal target volume should be contoured to above the cricoid cartilage for involvement of levels 1-2 of the axilla, the arytenoids for involvement of the ICLV, and to at least above the hyoid bone for SCV involvement (consider 3D historic boundary was the mastoid tip)
Boost Volumes CW_Boost CTV_PreChemo_LN	• Chest wall boosts should cover the surgical flaps (larger than a scar boost) • Adequate coverage of the medial chest wall beyond the scar should be ensured • Clinically involved unresected lymph nodes (pGTV_PreChemo_LN) will be expanded by a 1-2 cm margin, edited for clinical areas at risk and constrained to the primary elective nodal pCTVs to achieve the pCTV_PreChemo_LN • When boosting the ICLV or SCV, a composite plan should be developed during initial planning to ensure brachial plexus constraints are not exceeded

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX C: Principles of Radiation Therapy - continued

Coverage Criteria and Organ Constraints

- Grossly involved lymph nodes prior to chemotherapy (pGTV_PreChemo_LN) that are unresected should receive, at minimum, 100% of the target dose (V100% > 100%)

Target Volume	Definition	Criteria	Optimal
pGTV_PreChemo_LN	Unresected grossly involved lymph nodes (pre-treatment) as delineated using fused cross-sectional diagnostic imaging (CT with contrast; PET/CT) and edited for clinical areas at risk	V100%	100%
pCTV_ChestWall	CTV, subtracted 3 mm from the skin	V98%	≥ 98%
pCTV_Axilla	CTV, subtracted 5 mm from the skin	V98%	≥ 98%
pCTV_IMC	CTV, subtracted 5 mm from the skin	V98%	≥ 98%
pCTV_SCV	CTV, subtracted 3 mm from the skin, ensuring no overlap with the thyroid or the PRV_Esophagus (esophagus plus 3 mm)	V98%	≥ 98%
pCTV_PreChemo_LN	pGTV_PreChemo_LN plus 1-2 cm margin expansion (at minimum, per physician discretion), edited for clinical areas at risk and constrained to the primary elective nodal pCTVs	V98%	≥ 98%
PTV_ChestWall	pCTV plus 5 mm expansion in all directions except posteriorly (3 mm), subtracted 3 mm from the skin	V95%	≥ 95%
PTV_Axilla	pCTV plus 5 mm expansion in all directions, subtracted 5 mm from the skin	V95%	≥ 95%
PTV_IMC	pCTV plus 5 mm expansion in all directions except posteriorly (3 mm), subtracted 5 mm from the skin	V95%	≥ 95%
PTV_SCV	pCTV plus 5 mm expansion in all directions except medially (0 mm), subtracted 3 mm from the skin, ensuring no overlap with the thyroid or the PRV_Esophagus (esophagus plus 3 mm)	V95%	≥ 95%
PTV_PreChemo_LN	pCTV_PreChemo_LN plus 5 mm expansion in all directions, limited to the PTV for the elective nodal volumes within the primary plan	V95%	≥ 95%

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX C: Principles of Radiation Therapy - continued

Coverage Criteria and Organ Constraints - continued

Organ at Risk	Criteria ¹	Optimal	Acceptable
Lung_Ipsilateral	V 20 Gy	≤ 33%	N/A
	V 10 Gy	≤ 54%	
	V 5 Gy	≤ 65 Gy	≤ 75 Gy
	Dmean	≤ 20 Gy	N/A
Lung_Contralateral	V 20 Gy	≤ 8%	
Heart	V 20 Gy	≤ 4%	
	V 10 Gy	≤ 15%	
	Dmean	≤ 5 Gy	
Ventricle_Left	V 5 Gy	≤ 25%	
Left Anterior Descending Artery (LAD)	Dmax	≤ 25 Gy	
	V 15 Gy	≤ 10%	
Thyroid	Dmean	≤ 20 Gy	ALARA
Esophagus	Dmax	≤ 30 Gy	≤ 45 Gy

Organ at Risk	Criteria ¹	Optimal	Acceptable
BrachialPlexus_Ipsilateral ²	Dmax	≤ 52 Gy	N/A
Breast_Contralateral	Dmean	≤ 5 Gy	ALARA
Liver	Dmean	≤ 10 Gy	N/A
	Dmax	≤ 25 Gy	
Stomach	Dmean	≤ 5 Gy	
	Dmax	≤ 12 Gy	
CeliacPlexus_Gatroesophageal Junction (GEJ)	Dmax	≤ 10 Gy	
	Dmean	≤ 3 Gy	
Spinal Cord	Dmax	≤ 20 Gy	
Parotid_Ipsilateral	Dmean	≤ 26 Gy	≤ 36 Gy
Submandibular_Ipsilateral	Dmean	≤ 26 Gy	
Parotid_Contralateral	Dmax	≤ 10 Gy	
Submandibular_Contralateral	Dmax	≤ 10 Gy	N/A
Larynx	Dmean	≤ 20 Gy	≤ 30 Gy

ALARA = as low as reasonably achievable

V 20 Gy = volume (%) of the organ at risk receiving ≤ 20 Gy

V 5 Gy = volume (%) of the organ at risk receiving ≤ 5 Gy

Dmax = maximum point dose

V 15 Gy = volume (%) of the organ at risk receiving ≤ 15 Gy

Dmean = average point dose

V 10 Gy = volume (%) of the organ at risk receiving ≤ 10 Gy

¹ Criteria for organ constraints applicable for both daily (QD) and twice daily (BID) fractionation regimens

² Primary Plan. If sequential ICLV or SCV boost is planned, a composite plan will be created with the following constraints: Dmax ≤ 66 Gy, Dmean ≤ 63 Gy

Principles of Re-irradiation

- Prior radiation therapy records, including digital information and communication in medicine (DICOM) files, should be obtained and carefully reviewed. A composite plan should be created including both the radiation dose previously received and the radiation dose planned to be delivered.
- Re-irradiation should be discouraged if prior radiation therapy was completed within the past 2 years or if definitive dose cannot be safely delivered

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX D: Adjuvant Systemic Therapy Options

Note: Bone density should be monitored in postmenopausal patients, consider antiresorptive therapy for osteopenia and institute for osteoporosis. Calcium/vitamin D replacement is recommended for all patients.

Molecular Subtypes ¹	First Line Therapy	Considerations
TNBC ²	• No residual disease (pCR) ◦ BRCA negative or BRCA positive: Pembrolizumab 200 mg IV every 3 weeks for 9 cycles or pembrolizumab 400 mg every 6 weeks for 5 cycles • Residual disease (non-pCR) ◦ BRCA negative: Concurrent pembrolizumab and capecitabine; if pembrolizumab contraindicated, capecitabine alone ◦ BRCA positive: Olaparib 300 mg PO twice daily for 1 year or concurrent olaparib with pembrolizumab or sequential olaparib followed by pembrolizumab	N/A
ER+	• No residual disease (pCR) ◦ Premenopausal³ at diagnosis - OFS plus AI^{4,5} for 5-10 years⁶ - Tamoxifen for 5-10 years⁶ only if OFS and AI⁴ not feasible ◦ Postmenopausal at diagnosis - AI^{4,5} for 5-10 years⁶ - Tamoxifen for 5-10 years⁶ only if AI^{4,5} not feasible ◦ For patients with no residual disease, recommend adjuvant abemaciclib or ribociclib in high risk patients • Residual disease (non-pCR) ◦ BRCA negative: Endocrine therapy as above plus abemaciclib 150 mg PO twice daily for 2 years or ribociclib 400 mg PO daily for 21 days for each 28 day cycle for 3 years ◦ BRCA positive: Endocrine therapy as above plus olaparib. Consider abemaciclib or ribociclib after olaparib completed.	• Premenopausal ◦ Consider OFS plus tamoxifen for patients who cannot tolerate AI • Postmenopausal ◦ Consider adjuvant bisphosphonate
HER2+	• No residual disease (pCR): Trastuzumab plus pertuzumab for 1 year • Residual disease (non-pCR): Adjuvant T-DM1 for 1 year	• For residual disease (non-pCR), recommend neratinib⁷ for 1 year after completion of T-DM1 if HR+ and consider if HR- • For no residual disease (pCR), recommend discussion about neratinib⁷ for 1 year

AI = aromatase inhibitor

OFS = ovarian function suppression

pCR = pathological complete response

T-DM1 = ado-trastuzumab emtansine

¹ Consider clinical trials in all tumor subtypes

² For patients with pCR, see [Page 3](#) for surveillance

³ Male patients should be treated similarly to premenopausal patients. Use of AIs or fulvestrant should be accompanied by androgen deprivation therapy (medical/surgical).

⁴ AIs should only be used in patients who are clearly post menopausal (status post-surgical bilateral oophorectomy (BSO)], clinically suppressed on gonadotropin analogues, > 2 years without clinical menses if stopped. early due to chemotherapy, or naturally ceased menses for 1 year; for patients after hysterectomy and removal of ovaries are uncertain or age < 55 years, consider verifying with estrogen, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels. If definitive BSO, verification with hormone levels is not indicated.

⁵ AIs may not be an option if the patient is intolerant, concerns over bone density or patient declines therapy

⁶ Duration of endocrine therapy should be at least 5 years and may be extended up to 10 years based on patient tolerance and preference

⁷ Not on MD Anderson Cancer Center Formulary

APPENDIX E: Refractory, Recurrent or Metastatic Breast Cancer Systemic Therapy Treatment Options

Chemotherapy	Preferred single agents: Anthracyclines • Pegylated liposomal doxorubicin Taxanes • Paclitaxel Anti-metabolites • Capecitabine • Gemcitabine Other microtubule inhibitors • Vinorelbine • Eribulin Antibody drug conjugates • Sacituzumab govitecan¹ • Datopotamab deruxtecan^{2,3}
	Other single agents: • Docetaxel • Cisplatin • Ixabepilone • Carboplatin • Albumin-bound paclitaxel • Epirubicin
	Combination chemotherapy regimens: • AC (doxorubicin and cyclophosphamide) • CMF (cyclophosphamide, methotrexate, and fluorouracil) • Gemcitabine and carboplatin • EC (epirubicin and cyclophosphamide) • Gemcitabine and paclitaxel • Ixabepilone/capecitabine • Docetaxel and capecitabine
HER2 Based Therapies	First-line regimens for HER2-positive disease⁴: • Patients with trastuzumab naïve disease or those who recurred within 6 months after adjuvant trastuzumab ◦ Fam-trastuzumab deruxtecan⁵ • Patients with trastuzumab naïve disease or those who recurred > 12 months after adjuvant trastuzumab ◦ Pertuzumab plus trastuzumab and docetaxel ◦ Pertuzumab plus trastuzumab and paclitaxel ◦ T-DM1 (ado-trastuzumab emtansine) Other options (not considered preferred first options): • Trastuzumab with docetaxel • Trastuzumab with paclitaxel with or without carboplatin • Trastuzumab with vinorelbine • Trastuzumab with capecitabine • Tucatinib, capecitabine, and trastuzumab • Trastuzumab plus pertuzumab (if pertuzumab not previously given)
	Second line regimens and beyond (including those listed under first line but not used)²: • Lapatinib plus capecitabine • Trastuzumab plus lapatinib without cytotoxic therapy • Neratinib^{3,6} • Neratinib^{3,6} plus capecitabine • Trastuzumab plus capecitabine • Margetuximab plus chemotherapy (capecitabine, vinorelbine, gemcitabine, or eribulin) • Trastuzumab plus capecitabine plus tucatinib • Trastuzumab plus other agent

¹ Indicated in patients with TNBC or ER positive metastatic disease

² Indicated in patients with HR-positive/HER2-negative unresectable or metastatic disease

³ Not on MD Anderson Cancer Center Formulary

⁴ After maximal benefit achieved with chemotherapy, consider continuous anti-HER2 therapy alone or pertuzumab plus trastuzumab, if ER or PR positive, in combination with appropriate hormonal therapy (does not apply to T-DM1 or fam-trastuzumab deruxtecan)

⁵ Also indicated for HER2-low and HER2 ultra-low breast cancer

⁶ ERBB2 mutations without over expression of HER2; If ER positive, add endocrine based therapy

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX E: Refractory, Recurrent or Metastatic Breast Cancer Systemic Therapy Treatment Options - continued

Endocrine Based Therapies	• Aromatase inhibitors (AI) ◦ Anastrozole ◦ Letrozole ◦ Exemestane ◦ Exemestane plus everolimus ◦ AI with or without CDK 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) • Tamoxifen • Tamoxifen with everolimus • Abemaciclib single agent • Estrogen (estradiol) • Megestrol acetate	• Fulvestrant ◦ Fulvestrant with AI ◦ Fulvestrant with everolimus ◦ Fulvestrant with alpelisib for <i>PIK3CA</i> mutation ◦ Fulvestrant with or without CDK 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) ◦ Fulvestrant with capivasertib^{1,2} for <i>PIK3CA</i>, <i>AKT1</i>, or <i>PTEN</i> mutation ◦ Fulvestrant and palbociclib with inavolisib¹ for <i>PIK3CA</i> mutated endocrine resistant³ • Elacestrant for <i>ESR1</i> mutation
BRCA-positive directed therapies: • Olaparib • Talazoparib Triple Negative Breast Cancer with PD-L1 expression: • Pembrolizumab plus chemotherapy (gemcitabine with carboplatin or albumin bound paclitaxel or paclitaxel) Molecularly targeted agents along with <i>NTRK</i> fusion-directed: • Larotrectinib • Entrectinib • Repotrectinib MSI-H/dMMR-positive: • Pembrolizumab Total Mutation Burden-High (TMB-H: ≥ 10 muts/mb): • Pembrolizumab • Dostarlimab <i>RET</i>-fusion: • Selpercatinib Bone-directed therapies: • Zoledronic acid • Denosumab		

¹ Not on MD Anderson Cancer Center Formulary

² Indicated for advanced disease during or after previous AI therapy with or without CDK 4/6 inhibitor

³ Indicated for locally advanced or metastatic disease in patients with recurrence within 12 months of endocrine therapy

Department of Clinical Effectiveness V4

Approved by the Executive Committee of the Medical Staff on 08/19/2025

Copyright 2025 The University of Texas MD Anderson Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

PRINCIPLES OF INFLAMMATORY BREAST ONCOLOGIC SURGERY

Multidisciplinary Management of Inflammatory Breast Cancer

- Surgical management of breast cancer is an important aspect of curative intent therapy. Surgical decision-making is imbedded within the context of the multidisciplinary management of the breast oncology patient (both male and female).
- Patient participation in clinical trials when appropriate is strongly encouraged
- Breast surgery is performed 4-6 weeks after neoadjuvant chemotherapy
- Post-operative radiation therapy is administered 4 weeks after surgery

Diagnosis of Breast Malignancy

- Dedicated breast imaging at presentation should include bilateral diagnostic mammography, MRI breast with and without contrast, and bilateral nodal basin ultrasound to evaluate extent of disease
- Core needle biopsy is the preferred method of diagnosis of a palpable breast mass or a non-palpable breast imaging abnormality. Pathology should include biomarker assessment.
- FNA biopsy can be used for additional suspicious lesions in the ipsilateral breast to evaluate for multifocal/multi-centric disease and for diagnosis of metastases in suspicious regional nodes
- Placement of radiopaque clip marker with confirmation by imaging should be performed after needle biopsy
- Medical photography can be clinically useful to follow response and characterize extent of skin involvement
- Punch biopsy of the skin should be considered to document skin involvement
- The IBC Scoring System may be calculated to assist in diagnosing borderline cases. Refer to <https://www.komen.org/ibc-calculator-intro/>.

Clinical Staging of the Axilla

Bilateral axillary ultrasound and physical examination are recommended for clinical axillary staging in inflammatory breast cancer. Biopsy of suspicious axillary node(s) and placement of radiopaque clip marker if positive for metastasis is recommended.

Surgical Management

- Modified radical mastectomy (MRM) is standard of care in patients with IBC. MRM refers to total mastectomy with axillary level I/II dissection. Immediate breast reconstruction is contraindicated. Contralateral prophylactic surgery is not recommended.
- Consider referral to plastic surgery for immediate prophylactic lymphovenous bypass
- Referral to plastic surgery for delayed reconstruction and for possible lymphedema intervention is recommended
- Psychosocial and body image concerns should be addressed prior to surgery
- Incisions for total mastectomy should be placed to facilitate the removal of the preponderance of breast tissue to achieved local disease control and decrease the risk of recurrent breast cancer. In IBC, this includes care to include excision of all grossly involved skin. Reconstructive approaches may be warranted given the extent of skin involvement and excision.
- Anatomical boundaries of mastectomy remain uniform in order to remove the entire breast parenchyma. This includes the second rib superiorly, the upper border of the rectus sheath inferiorly, the lateral border of the sternum medially and the latissimus dorsi muscle laterally. Care should be taken to excise glandular tissue which extends into the axilla. Pectoralis fascia is commonly excised. Fascia of the serratus anterior and rectus sheath should be preserved.

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

PRINCIPLES OF INFLAMMATORY BREAST ONCOLOGIC SURGERY - continued

Surgical Management - continued

- Mastectomy flaps should be elevated in a manner that facilitates the removal of essentially all breast tissue to reduce risk of recurrence and that preserves the overlying subcutaneous tissue and its vascular plexus to minimize the risk of flap necrosis
- Localized excision of the pectoralis muscle is sometimes necessary to achieve clear margins
- Drains must be optimally placed to prevent seroma formation and reduce seroma-related morbidity after total mastectomy in order to avoid delays to adjuvant treatment

Surgical Management of the Axilla

- ALND (level I and II) is indicated in patients with biopsy proven clinically node positive disease and pathologic positive nodal involvement. Level III dissection may be considered in patients with level III residual disease after neoadjuvant chemotherapy.
- Axillary lymph node dissection entails identification of the axillary vein and latissimus dorsi, pectoralis major, pectoralis minor, serratus anterior and subscapularis muscles is essential for the resection of sufficient level I and II axillary nodes for breast cancer staging and adjuvant treatment planning
- Removal of Rotter's nodes is not typically indicated but should be considered in patients with locally advanced breast cancer, N2 disease and if identified as suspicious by preoperative imaging
- A target minimum of 10 axillary nodes should be removed to ensure a high-level confidence that the remaining lymph nodes are negative
- Evaluation by a physical therapist for improved range of motion and screening for lymphedema is recommended

Neoadjuvant Systemic Therapy

- Neoadjuvant systemic therapy is standard of care in patients with IBC
- Extent of disease in the breast and regional nodes should be determined and documented prior to initiation of neoadjuvant systemic therapy

Management of Local-regional Recurrence

- Breast imaging including mammograms (if recurrence after breast conserving surgery), breast/chest wall and bilateral nodal basin ultrasound and MRI when appropriate should be obtained
- Diagnosis by core needle biopsy including biomarker evaluation is recommended
- Staging should be performed to evaluate for distant metastatic disease, and PET-CT is preferred to understand the extent of lymph node involvement
- Multimodality therapy is recommended including systemic neoadjuvant therapy, and surgical resection followed by systemic adjuvant therapy and radiation therapy

Stage IV Disease

- For patients who have a life expectancy of > 6 months and can tolerate systemic therapy and local radiation therapy, consider multimodal therapy including surgical resection
- In selected patients with oligometastatic disease, excellent response to systemic therapy and acceptable performance status, surgery of the primary tumor and nodal involvement may be considered to achieve no evidence of disease (NED) status. Definitive management of the oligometastatic disease is also recommended.
- If localized stage IV to the contralateral axilla, consider contralateral ALND followed by radiation therapy

Special Considerations

Palliative mastectomy may be considered in patients with advanced local progression, with symptomatic fungating, and with bleeding tumors not responsive to systemic therapy

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Akay, C. L., Ueno, N. T., Chisholm, G. B., Hortobagyi, G. N., Woodward, W. A., Alvarez, R. H., . . . Babiera, G. V. (2014). Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. *Cancer*, 120(9), 1319-1328. <https://doi.org/10.1002/cncr.28550>
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., . . . Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *The New England Journal of Medicine*, 380(20), 1929-1940. <https://doi.org/10.1056/NEJMoa1813904>
- Bardia, A., Jhaveri, K., Im, S. A., Pernas, S., De Laurentiis, M., Wang, S., . . . Pistilli, B. (2024). Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. *Journal of Clinical Oncology*, 43(3), 285-296. <https://doi.org/10.1200/JCO.24.00920>
- Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., . . . Bardia, A. (2022). Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. *Journal of Clinical Oncology*, 40(28), 3246-3256. <https://doi.org/10.1200/JCO.22.00338>
- DeSnyder, S. M., Mittendorf, E. A., Le-Petross, C., Krishnamurthy, S., Whitman, G. J., Ueno, N. T., . . . Lucci, A. (2018). Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. *Clinical Breast Cancer*, 18(1), e73-e77. <https://doi.org/10.1016/j.clbc.2017.06.014>
- Fouad, T. M., Barrera, A. M. G., Reuben, J. M., Lucci, A., Woodward, W. A., Stauder, M. C., . . . Ueno, N. T. (2017). Inflammatory breast cancer: A proposed conceptual shift in the UICC-AJCC TNM staging system. *The Lancet Oncology*, 18(4), e228-e232. [https://doi.org/10.1016/S1470-2045\(17\)30192-4](https://doi.org/10.1016/S1470-2045(17)30192-4)
- Fu, J. B., Manne, R., Ngo-Huang, A., Tennison, J. M., Ng, A. H., Andersen, C., Woodward, W. A., & Bruera, E. (2024). Onabotulinum toxin injections for shoulder and chest wall muscle pain in breast cancer survivors: Retrospective study - preliminary report. *BMJ Supportive & Palliative Care*, 14(e2), e2094-e2099. <https://doi.org/10.1136/spcare-2024-004987>
- Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., . . . Solit, D. B. (2018). HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature*, 554(7691), 189-194. <https://doi.org/10.1038/nature25475>
- Jagsi, R., Mason, G., Overmoyer, B. A., Woodward, W. A., Badve, S., Schneider, R. J., . . . Miller, K. D. (2022). Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. *Breast Cancer Research and Treatment*, 192, 235-243. <https://doi.org/10.1007/s10549-021-06434-x>
- Jhaveri, K. L., Goldman, J. W., Hurvitz, S. A., Guerrero-Zotano, A., Unni, N., Brufsky, A., . . . Wildiers, H. (2022). Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2 -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. *Journal of Clinical Oncology*, 40(Suppl 16), 1028. https://doi.org/10.1200/JCO.2022.40.16_suppl.1028
- Le-Petross, H. T., Balema, W., & Woodward, W. A. (2021). Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: A narrative review. *Chinese Clinical Oncology*, 10(6), 58-67. Retrieved from <https://cco.amegroups.com/article/view/86363/html>
- Li, Z. W., Zhang, M., Yang, Y. J., Zhou, Z. J., Liu, Y. L., Li, H., . . . Wang, D. W. (2020). Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: A SEER population-based retrospective study. *PeerJ*, 8(2), e8512. <https://doi.org/10.7717/peerj.8512>

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

- Lu, J., Blakely, C. M., Barve, M., Chung, C. H., Waqar, S. N., Hu, X., . . . Le Tourneau, C. (2022). 173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2. *Annals of Oncology*, 33(Suppl 3), S204-S205. <https://doi.org/10.1016/j.annonc.2022.03.192>
- Ma, C. X., Luo, J., Freedman, R. A., Pluard, T. J., Nangia, J. R., Lu, J., . . . Bose, R. (2022). The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer. *Clinical Cancer Research*, 28(7), 1258-1267. <https://doi.org/10.1158/1078-0432.CCR-21-3418>
- Maio, M., Ascierto, P. A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P. A., . . . Marabelle, A. (2021). Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. *Journal of Clinical Oncology*, 39(Suppl 15), 2565. https://doi.org/10.1200/JCO.2021.39.15_suppl.2565
- Masuda, H., Brewer, T. M., Liu, D. D., Iwamoto, T., Shen, Y., Hsu, L., . . . Ueno, N. T. (2014). Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. *Annals of Oncology*, 25(2), 384-391. <https://doi.org/10.1093/annonc/mdt525>
- Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., . . . Toi, M. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *The New England Journal of Medicine*. 376(22), 2147-2159. <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1612645>
- MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy
 Advance Care Planning (ACP) Conversation Workflow (ATT1925)
- Muzaffar, M., Johnson, H. M., Vohra, N. A., Liles, D., & Wong, J. H. (2018). The impact of locoregional therapy in nonmetastatic inflammatory breast cancer: A population-based study. *International Journal of Breast Cancer*, 2018, 1-6. <https://doi.org/10.1155/2018/6438635>
- National Comprehensive Cancer Network. (2025). *Breast Cancer* (NCCN Guideline Version 4.2025) Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- Niikura, N., Liu, J., Costelloe, C. M., Palla, S. L., Madewell, J. E., Hayashi, N., . . . Ueno, N. T. (2011). Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. *The Oncologist*, 16(6), 772-782. <https://doi.org/10.1634/theoncologist.2010-0378>
- RADCOMP Atlas Committee. (2016, February 23). *RADCOMP Breast Atlas*. NRG Oncology. Retrieved from <https://www.nrgoncology.org/About-Us/Center-for-Innovation-in-Radiation-Oncology/Breast-Cancer/RADCOMP-Breast-Atlas>
- Rosso, K. J., Tadros, A. B., Weiss, A., Warneke, C. L., DeSnyder, S., Kuerer, H., . . . Lucci, A. (2017). Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery. *Annals of Surgical Oncology*, 24(10), 2981-2988. <https://doi.org/10.1245/s10434-017-5952-x>
- Rueth, N. M., Lin, H. Y., Bedrosian, I., Shaitelman, S. F., Ueno, N. T., Shen, Y., & Babiera, G. (2014). Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: An analysis of treatment and survival trends from the National Cancer Database. *Journal of Clinical Oncology*, 32(19), 2018-2024. <https://doi.org/10.1200/JCO.2014.55.1978>
- Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., . . . Tolaney, S. M. (2022). LBA76 overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). *Annals of Oncology*, 33(Suppl 7), S1386. <https://doi.org/10.1016/j.annonc.2022.08.012>

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

- Rugo, H. S., Bardia, A., Marmé, F., Cortes, J., Schmid, P., Loirat, D., . . . Tolaney, S. M. (2022). Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. *Journal of Clinical Oncology*, 40(29), 3365-3376. <https://doi.org/10.1200/JCO.22.01002>
- Rugo, H. S., Im, S. A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., . . . Gradishar, W. J. (2021). Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. *JAMA Oncology*, 7(4), 573-584. <https://doi.org/10.1001/jamaoncol.2020.7932>
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., . . . O'Shaughnessy, J. (2020). Pembrolizumab for early triple-negative breast cancer. *The New England Journal of Medicine*, 382(9), 810-821. <https://doi.org/10.1056/NEJMoa1910549>
- Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukiela-Budny, B., Stroyakovskiy, D., . . . Hortobagyi, G. (2024). Ribociclib plus endocrine therapy in early breast cancer. *The New England Journal of Medicine*, 390(12), 1080-1091. <https://doi.org/10.1056/NEJMoa2305488>
- Stecklein, S. R., Rosso, K. J., Nuanjing, J., Tadros, A. B., Weiss, A., DeSnyder, S. M., . . . Woodward, W. A. (2019). Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach. *Practical Radiation Oncology*, 9(6), 402-409. <https://doi.org/10.1016/j.prro.2019.05.011>
- Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., . . . Rugo, H. S. (2023). Capivasertib in hormone receptor-positive advanced breast cancer. *The New England Journal of Medicine*, 388(22), 2058-2070. <https://doi.org/10.1056/NEJMoa2214131>
- Turner, N. C., Im, S. A., Saura, C., Juric, D., Loibl, S., Kalinsky, K., . . . Jhaveri, K. L. (2024). Inavolisib-based therapy in PIK3CA-Mutated advanced breast cancer. *The New England Journal of Medicine*, 391(17), 1584-1596. <https://doi.org/10.1056/NEJMoa2404625>
- Ueno, N. T., Espinosa Fernandez, J. R., Cristofanilli, M., Overmoyer, B., Rea, D., Berdichevski, F., . . . Woodward, W. A. (2018). International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. *Journal of Cancer*, 9(8), 1437-1447. <https://doi.org/10.7150/jca.23969>
- Warren, L. E. G., Guo, H., Regan, M. M., Nakhli, F., Yeh, E. D., Jacene, H. A., . . . Bellon, J. R. (2015). Inflammatory breast cancer: Patterns of failure and the case for aggressive locoregional management. *Annals of Surgical Oncology*, 22(8), 2483-2491. <https://doi.org/10.1245/s10434-015-4469-4>
- Woodward, W. A. (2015). Should surgery referral be standard practice in metastatic inflammatory breast cancer? *Annals of Surgical Oncology*, 22(8), 2466-2467. <https://doi.org/10.1245/s10434-015-4513-4>
- Woodward, W. A., Ueno, N. T., Kuerer, H. M., Lucci, A., & Shen, Y. (2018). Reply to “A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18.” *The Breast*, 39, 148-149. <https://doi.org/10.1016/j.breast.2018.01.008>
- Yamauchi, H., Woodward, W. A., Valero, V., Alvarez, R. H., Lucci, A., Buchholz, T. A., . . . Ueno, N. T. (2012). Inflammatory breast cancer: What we know and what we need to learn. *The Oncologist*, 17(7), 891-899. <https://doi.org/10.1634/theoncologist.2012-0039>
- Zhang, H., Ma, G., Du, S., Sun, J., Zhang, Q., Yuan, B., & Luo, X. (2019). Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: A SEER population-based study. *PeerJ*, 7(9), e7659. <https://doi.org/10.7717/peerj.7659>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Inflammatory Breast Cancer Clinical providers at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Rachel Layman, MD (Breast Medical Oncology)
Anthony Lucci, MD (Breast Surgical Oncology)
Wendy Woodward, MD, PhD (Breast Radiation Oncology)

Workgroup Members

Angela Alexander, PhD (Breast Medical Oncology)	Jessica Leung, MD (Breast Imaging)
Edward Chang, MD (Plastic Surgery)	Bora Lim, MD (Breast Medical Oncology)
Vivian Chiv, MSN, RN (Breast Medical Oncology)	Jonathan Malara, PharmD (Pharmacy Clinical Programs)
Sarah DeSnyder, MD (Breast Surgical Oncology)	Angela Marx, BSN, RN (Breast Medical Oncology)
Elizabeth FitzSullivan, MD (Breast Surgical Oncology)	Azadeh Nasrazadani, MD, PhD (Breast Medical Oncology)
Wendy Garcia, BS♦	Valerie Reed, MD (Radiation Oncology)
Yun Gong, MD (Pathology)	Sadia Saleem, MD (Breast Medical Oncology)
Chelain Goodman, MD, PhD (Breast Radiation Oncology)	Mark Schaverien, MD (Plastic Surgery)
Erin Grannan, PharmD (Pharmacy Clinical Programs)	Michael Stauder, MD (Breast Radiation Oncology)
Lei Huo, MD, PhD (Pathology - Anatomical)	Susie Sun, MD (Breast Surgical Oncology)
Savitri Krishnamurthy, MD (Pathology - Anatomical)	Vicente Valero, MD (Breast Medical Oncology)
Huong Le-Petross, MD (Breast Imaging)	Mary Lou Warren, DNP, APRN, CNS-CC♦
	Gary Whitman, MD (Breast Imaging)

♦Clinical Effectiveness Development Team